Micafungin
Total Payments
$623,864
Transactions
23
Doctors
6
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $623,864 | 23 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $598,953 | 18 | 96.0% |
| Travel and Lodging | $19,671 | 3 | 3.2% |
| Consulting Fee | $5,180 | 1 | 0.8% |
| Food and Beverage | $59.79 | 1 | 0.0% |
Payments by Type
Research
$598,953
18 transactions
General
$24,911
5 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents | Astellas Pharma Europe BV | $180,883 | 0 |
| Posaconazole Versus Micafungin Prophylaxis in Patients with Acute Leukemia or Myelodsplastic Syndrome Undergoing Induction Chemotherapy | Astellas Pharma Global Development | $129,588 | 0 |
| Candida and Staphylococcus aureus: A Polymicrobial Biofilm.Characterization & Evaluation of Antimicrobial Interventions | Astellas Pharma Global Development | $96,357 | 0 |
| Candida Blood Stream Infections: Defining Attributable Mortality and Building Predictive Models for Mortality and Antifungal Resistance. | Astellas Pharma Global Development | $96,000 | 0 |
| Differential Phosphorylation to Define the Mechanism of the Paradoxical Effect to Distinguish Micafungin and Anidulafungin from Caspofungin | Astellas Pharma Global Development | $56,300 | 0 |
| Determining the prevalence of echinocandin-resistance in clinically relevant Candida isolates and the influence of these organisms on clinical outcome: a single center, retrospective, case-control pilot study | Astellas Pharma Global Development | $36,654 | 0 |
| A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | Astellas Pharma Global Development | $3,171 | 5 |
Top Doctors Receiving Payments for Micafungin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Ann Arbor, MI | $595,782 | 13 |
| , MD | Infectious Disease | Gainesville, FL | $24,911 | 5 |
| David Kaufman | Pediatrics | Charlottesville, VA | $634.23 | 1 |
| , M.D | Infectious Disease | New York, NY | $634.23 | 1 |
| , M.D | Pediatric Infectious Diseases | Orange, CA | $634.23 | 1 |
| , MD | Neonatal-Perinatal Medicine | Durham, NC | $634.23 | 1 |
| Danny Benjamin | — | Durham, NC | $634.23 | 1 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $418,070
- Astellas Pharma Europe BV $180,883
- Astellas Pharma Inc $24,911
Product Information
- Type Drug
- Total Payments $623,864
- Total Doctors 6
- Transactions 23
About Micafungin
Micafungin is a drug associated with $623,864 in payments to 6 healthcare providers, recorded across 23 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2017. In 2017, $623,864 was paid across 23 transactions to 6 doctors.
The most common payment nature for Micafungin is "Unspecified" ($598,953, 96.0% of total).
Micafungin is associated with 7 research studies, including "A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents" ($180,883).